Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141370 | 0.84 | MAP2K1 (0.54) | RAB9ANPC1SMN1; SMN2TP53GAA | |
| SCHEMBL27001673 | 0.81 | GAA (0.59) | RAB9ANPC1SMN1; SMN2TP53GAA | |
| SCHEMBL7507358 | 0.81 | GAA (0.55) | RAB9ANPC1SMN1; SMN2TP53GAA | |
| SCHEMBL11033825 | 0.81 | GAA (0.51) | RAB9ANPC1SMN1; SMN2TP53GAA | |
| SCHEMBL21401162 | 0.80 | GAA (0.57) | RAB9ANPC1SMN1; SMN2TP53GAA | |
| SCHEMBL7498832 | 0.78 | GAA (0.51) | RAB9ANPC1SMN1; SMN2TP53GAA | |
| SCHEMBL3953041 | 0.78 | GAA (0.55) | RAB9ANPC1SMN1; SMN2TP53GAA | |
| SCHEMBL3536906 | 0.76 | TP53 (0.49) | RAB9ANPC1SMN1; SMN2TP53GAA | |
| 4-Imidazolecarboxylic Acid SCHEMBL1662601 | 0.73 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL27473022 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450795-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003047576-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | claimed |
| US-7572916-B2 | Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-11 | — | — | US | disclosed |
| US-20070293680-A1 | For the preparation of (R)-(+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl2(1H)-quinolinone; farnesyl tranferase inhibitory activity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-20 | — | — | US | disclosed |
| US-7253183-B2 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-07 | — | — | US | disclosed |
| EP-1450795-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003047576-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0603309-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293680-A1 | For the preparation of (R)-(+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl2(1H)-quinolinone; farnesyl tranferase inhibitory activity | FNTB, CYP4F2, FNTA | RAB9A 854/4885NPC1 1829/4885SMN1; SMN2 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.